These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 12038784)

  • 41. Continuous prophylaxis with recombinant factor IX Fc fusion protein and conventional recombinant factor IX products: comparisons of efficacy and weekly factor consumption.
    Iorio A; Krishnan S; Myrén KJ; Lethagen S; McCormick N; Yermakov S; Karner P
    J Med Econ; 2017 Apr; 20(4):337-344. PubMed ID: 27885871
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B.
    Shapiro AD; Di Paola J; Cohen A; Pasi KJ; Heisel MA; Blanchette VS; Abshire TC; Hoots WK; Lusher JM; Negrier C; Rothschild C; Roth DA
    Blood; 2005 Jan; 105(2):518-25. PubMed ID: 15383463
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacokinetics of a novel extended half-life glycoPEGylated factor IX, nonacog beta pegol (N9-GP) in previously treated patients with haemophilia B: results from two phase 3 clinical trials.
    Tiede A; Abdul-Karim F; Carcao M; Persson P; Clausen WHO; Kearney S; Matsushita T; Negrier C; Oldenburg J; Santagostino E; Young G
    Haemophilia; 2017 Jul; 23(4):547-555. PubMed ID: 28233381
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacokinetics of plasma-derived and recombinant factor IX - implications for prophylaxis and on-demand therapy.
    Björkman S
    Haemophilia; 2013 Nov; 19(6):808-13. PubMed ID: 23786333
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Progress in the treatment of bleeding disorders.
    Bergman GE
    Thromb Res; 2011 Jan; 127 Suppl 1():S3-5. PubMed ID: 21035836
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacokinetic analysis of plasma-derived and recombinant F IX concentrates in previously treated patients with moderate or severe hemophilia B.
    Ewenstein BM; Joist JH; Shapiro AD; Hofstra TC; Leissinger CA; Seremetis SV; Broder M; Mueller-Velten G; Schwartz BA;
    Transfusion; 2002 Feb; 42(2):190-7. PubMed ID: 11896334
    [TBL] [Abstract][Full Text] [Related]  

  • 47. PROLONG-9FP clinical development program--phase I results of recombinant fusion protein linking coagulation factor IX with recombinant albumin (rIX-FP).
    Santagostino E
    Thromb Res; 2013 Mar; 131 Suppl 2():S7-10. PubMed ID: 23537724
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Phase I/II, open-label, multicenter, safety, efficacy and PK study of a recombinant coagulation factor IX albumin fusion protein (rIX-FP) in subjects with hemophilia B.
    Martinowitz U; Lubetsky A
    Thromb Res; 2013 Mar; 131 Suppl 2():S11-4. PubMed ID: 23537721
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Recombinant Factor IX Fc Fusion Protein Maintains Full Procoagulant Properties and Exhibits Prolonged Efficacy in Hemophilia B Mice.
    Toby GG; Liu T; Buyue Y; Zhang X; Bitonti AJ; Pierce GF; Sommer JM; Jiang H; Peters RT
    PLoS One; 2016; 11(2):e0148255. PubMed ID: 26840952
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Sustained release of transgenic human factor IX: preparation, characterization, and in vivo efficacy.
    Chang LC; Yang CY; Chua AC; Lin YJ; Lai SM
    Mol Pharm; 2011 Oct; 8(5):1767-74. PubMed ID: 21842870
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Continuous intravenous infusion of a plasma-derived factor IX concentrate (Mononine) in haemophilia B.
    Hoots WK; Leissinger C; Stabler S; Schwartz BA; White G; Dasani H; Massion C; Negrier C; Schindel F; Schulman S
    Haemophilia; 2003 Mar; 9(2):164-72. PubMed ID: 12614367
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Safety, pharmacokinetics, and pharmacodynamics of a next-generation subcutaneously administered coagulation factor IX variant, dalcinonacog alfa, in previously treated hemophilia B patients.
    You CW; Hong SB; Kim S; Shin HJ; Kim JS; Han JW; Kim SJ; Kim DY; Lee M; Levy H
    J Thromb Haemost; 2021 Apr; 19(4):967-975. PubMed ID: 33540485
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicentre phase I/III study in previously treated patients with severe (FIX level <1%) or moderately severe (FIX level ≤2%) haemophilia B.
    Windyga J; Lissitchkov T; Stasyshyn O; Mamonov V; Rusen L; Lamas JL; Oh MS; Chapman M; Fritsch S; Pavlova BG; Wong WY; Abbuehl BE
    Haemophilia; 2014 Jan; 20(1):15-24. PubMed ID: 23834666
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The manufacturing process for recombinant factor IX.
    Harrison S; Adamson S; Bonam D; Brodeur S; Charlebois T; Clancy B; Costigan R; Drapeau D; Hamilton M; Hanley K; Kelley B; Knight A; Leonard M; McCarthy M; Oakes P; Sterl K; Switzer M; Walsh R; Foster W
    Semin Hematol; 1998 Apr; 35(2 Suppl 2):4-10. PubMed ID: 9565160
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prophylaxis in factor IX deficiency product and patient variation.
    Kisker CT; Eisberg A; Schwartz B;
    Haemophilia; 2003 May; 9(3):279-84. PubMed ID: 12694518
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Nonacog beta pegol in previously treated children with hemophilia B: results from an international open-label phase 3 trial.
    Carcao M; Zak M; Abdul Karim F; Hanabusa H; Kearney S; Lu MY; Persson P; Rangarajan S; Santagostino E
    J Thromb Haemost; 2016 Aug; 14(8):1521-9. PubMed ID: 27174727
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Continuous infusion factor replacement in haemophilia B during and after cardiac surgery: the better choice?
    Farid S; Sewaralthahab S; Smith HP
    BMJ Case Rep; 2020 Nov; 13(11):. PubMed ID: 33257355
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Confirmation of longer FIX activity half-life with prolonged sample collection after single doses of nonacog alfa in patients with haemophilia B.
    Hua B; Wu R; Sun F; Luo B; Alvey C; Labadie R; Qu PR; Korth-Bradley JM; Rendo P
    Thromb Haemost; 2017 Jun; 117(6):1052-1057. PubMed ID: 28331929
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Systematic review and analysis of efficacy of recombinant factor IX products for prophylactic treatment of hemophilia B in comparison with rIX-FP.
    Davis J; Yan S; Matsushita T; Alberio L; Bassett P; Santagostino E
    J Med Econ; 2019 Oct; 22(10):1014-1021. PubMed ID: 31094591
    [No Abstract]   [Full Text] [Related]  

  • 60. Emerging drugs for hemophilia B.
    Mannucci PM; Franchini M
    Expert Opin Emerg Drugs; 2014 Sep; 19(3):407-14. PubMed ID: 25098797
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.